LFWD Share Price Performance
US$6.57
-10.71 (-61.98%)
67.2% undervalued intrinsic discount
US$20.00
Fair Value
Price US$6.57
AnalystConsensusTarget US$20.00
AnalystHighTarget US$120.00
AnalystLowTarget US$4.50
Fair ValueUS$20.00
Share Pricen/a
Lifeward Ltd. Stock Price
- 3 Narratives written by author
- 0 Comments on narratives written by author
- 12 Fair Values set on narratives written by author
LFWD Community Narratives
AN
Fair Value US$20 67.2% undervalued intrinsic discount
Expanding International Healthcare Access And Efficiencies Will Unlock Value
0users have liked this narrative
0users have commented on this narrative
9users have followed this narrative
AN
Fair Value US$120 94.5% undervalued intrinsic discount
Global Aging And Robotics Integration Will Unlock New Markets
0users have liked this narrative
0users have commented on this narrative
1users have followed this narrative
AN
Fair Value US$4.5 46.0% overvalued intrinsic discount
Slow Medicare Reimbursements Will Undermine Efficiency But Foster Resilience
0users have liked this narrative
0users have commented on this narrative
0users have followed this narrative
Expanding International Healthcare Access And Efficiencies Will Unlock Value
Key Takeaways Demographic shifts and expanded healthcare access drive sustained, multi-year demand for mobility and rehabilitation solutions, supporting higher growth and a larger addressable market. Increased operational efficiency, portfolio diversification, and payer engagement aid revenue growth, improve margins, and strengthen overall financial performance.Read more
104
users have viewed this narrative0users have liked this narrative
0users have commented on this narrative
9users have followed this narrative
AN
US$20
67.2% undervalued intrinsic discount
Fair Value
Profit Margin
13.08%
Future PE
2.61x
Price in 2029
US$14.52
Global Aging And Robotics Integration Will Unlock New Markets
Key Takeaways Lifeward is positioned for significant growth from increased global demand, product innovation, and operational scaling, potentially outpacing current analyst expectations on both revenue and margins. Strategic advantages in AI integration, patient-focused leadership, and proven international expansion provide unique access to high-value market segments and sustainable long-term profitability.Read more
63
users have viewed this narrative0users have liked this narrative
0users have commented on this narrative
1users have followed this narrative
AN
US$120
94.5% undervalued intrinsic discount
Fair Value
Profit Margin
7.96%
Future PE
16.87x
Price in 2029
US$87.07
Slow Medicare Reimbursements Will Undermine Efficiency But Foster Resilience
Key Takeaways Heavy reliance on a few flagship products and reimbursement delays expose Lifeward to margin pressure, cash flow risks, and regulatory or competitive setbacks. Expansion opportunities and operational improvements are offset by global pricing pressure, high upfront costs, and required ongoing investment, delaying meaningful profitability.Read more
16
users have viewed this narrative0users have liked this narrative
0users have commented on this narrative
0users have followed this narrative
AN
US$4.5
46.0% overvalued intrinsic discount
Fair Value
Profit Margin
0.097%
Future PE
1.43kx
Price in 2029
US$5.71
Trending Discussion
Recently Updated Narratives
AN
LFWD: Higher Fair Value Assumptions Will Support Future Cash Flow
Fair Value: US$20 67.2% undervalued intrinsic discount
9 fair values setusers have set this as their fair value
0 commentsusers have commented on this narrative
0 likesusers have liked this narrative
AN
LFWD: Reverse Split And Convertible Notes Will Support Future Upside
Fair Value: US$120 94.5% undervalued intrinsic discount
1 fair value setusers have set this as their fair value
0 commentsusers have commented on this narrative
0 likesusers have liked this narrative
AN
LFWD: Convertible Notes And Share Actions Will Drive Future P E Repricing
Fair Value: US$4.5 46.0% overvalued intrinsic discount
0 fair values setusers have set this as their fair value
0 commentsusers have commented on this narrative
0 likesusers have liked this narrative
Snowflake Analysis
Lifeward Ltd. Key Details
Last Reported Earnings
Dec 31, 2025
Next Reporting Earnings
n/a
- -5.26
- 38.25%
- -90.38%
- 33.3%
About LFWD
- Founded
- 2001
- Employees
- 81
- CEO
- WebsiteView website
Lifeward Ltd., a medical device company, designs, develops, and commercializes technologies that enable mobility and wellness in rehabilitation and daily life for individuals with physical and neurological conditions in the United States, Europe, Germany, the Asia-Pacific, and internationally. It offers ReWalk personal exoskeleton and rehabilitation exoskeleton devices for individuals with spinal cord injury; ReStore Exo-Suit, a soft exo-suit intended for use in the rehabilitation of individuals with lower limb disability due to stroke; AlterG Anti-Gravity System for use in physical and neurological rehabilitation and athletic training; MyoCycle devices; and ReBoot, a personal soft exo-suit for home and community use by individuals’ post-stroke. The company markets and sells its products directly to institutions and individuals, as well as through third-party distributors. The company was formerly known as ReWalk Robotics Ltd. and changed its name to Lifeward Ltd. in September 2024. Lifeward Ltd. was incorporated in 2001 and is based in Yokneam Illit, Israel.
